Therapy News and Research

RSS

Venom-based nanoparticles improve gene therapy for fighting glioma

An ingredient in the venom of the "deathstalker" scorpion could help gene therapy become an effective treatment for brain cancer, scientists are reporting. The substance allows therapeutic genes - genes that treat disease - to reach more brain cancer cells than current approaches, according to the study in ACS Nano, a monthly journal.

12 Aug 2010

Einstein College receives grant to develop stem cell-based therapies

Scientists at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $10.8 million grant to develop stem cell-based therapies that could be used to mitigate radiation-induced gastrointestinal syndrome - part of acute radiation syndrome (ARS) - for military personnel, first responders and the general public. The Einstein research, funded by the federal Centers for Medical Countermeasures Against Radiation, is part of a program coordinated by the National Institute of Allergy and Infectious Diseases.

12 Aug 2010

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Amgen today announced top-line results from a randomized Phase 3 trial evaluating Vectibix as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone.

12 Aug 2010

BMI indicates breast cancer risk in women using postmenopausal hormone therapy

Using postmenopausal hormone therapy for more than 15 years increases a woman's risk of developing breast cancer, particularly among leaner women according to research at the Keck School of Medicine of the University of Southern California (USC).

12 Aug 2010

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.

11 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

TomTec releases new version of 2D Cardiac Performance Analysis package

TomTec launches the latest version of its 2D Cardiac Performance Analysis package as part of TomTec's Image-Arena™ multimodality imaging solution.

11 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Molecular imaging helps physicians determine patient suitability for ICD therapy

A study published in the August Journal of Nuclear Medicine (JNM) finds that molecular imaging-a non-invasive imaging procedure-can identify high-risk patients with potentially life-threatening cardiovascular conditions and help physicians determine which patients are best suited for implantable cardioverter defibrillator (ICD) therapy.

11 Aug 2010

Cramer selects Neolane to support marketing communication programs for clients in healthcare practice

Enterprise marketing software provider Neolane, Inc. today announced that it has been selected by digital marketing and events solution company Cramer to support more effective marketing communications programs for its clients, specifically in its healthcare practice. The first program to benefit from Neolane's comprehensive, flexible marketing automation platform is a Cramer biopharmaceutical client that was seeking to improve the results of an on-going patient communications program that relies on targeted, personalized communications across multiple channels to support patient therapy.

11 Aug 2010

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

OptiNose Inc. announced today that a subgroup analysis of positive Phase II trial results has been published in the July/August issue of the American Journal of Rhinology & Allergy.

11 Aug 2010

ITI signs NPWT contract with MAGNET

Innovative Therapies Inc. announced today the signing of a negative pressure wound therapy contract with the Mid-Atlantic Group Network of Shared Services, encompassing both rental and sales of ITI's proprietary NPWT technology.

11 Aug 2010

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Researchers to develop a prototype for laser based radiation therapy

Currently, new treatment facilities for radiation therapy with ions are built all over the world. These particles destroy cancer cells and have a better ability to spare the surrounding healthy tissue than other techniques. Today, accelerated hydrogen and carbon ions are mainly used to treat inoperable tumors in organs like the brain and bone marrow, which are sensitive to radiation therapy.

11 Aug 2010

Immunomedics receives additional patent for CD74 target

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.

11 Aug 2010

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.

11 Aug 2010

Bluhm Cardiovascular Institute implants two Heartware ventricular assist devices

The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs) currently available for study in humans. VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both (BiVAD) at once. This is the first time that two Heartware VADs have been implanted in the left and right ventricles anywhere in North America—a "game changer" in the realm of heart assist devices according to Patrick M. McCarthy, MD, chief of the hospital's division of cardiac surgery and director of the hospital's Bluhm Cardiovascular Institute.

11 Aug 2010

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab A/S announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant.

11 Aug 2010

Georgia Institute receives EUREKA grant to design brain tumor treatment

The Georgia Institute of Technology has received a EUREKA grant from the National Institutes of Health (NIH) to design a new way to treat invasive brain tumors by capturing the migrating cells that spread the disease. The EUREKA -- Exceptional, Unconventional Research Enabling Knowledge Acceleration -- program helps scientists test new, unconventional ideas or tackle major methodological or technical challenges.

11 Aug 2010

Study finds hormone replacement therapy increases breast cancer risk

A new analysis of the California Teachers Study, which analyzed hormone replacement therapy use among 2,857 women for almost 10 years, underscores the need for personalized risk-benefit discussions before women begin hormone therapy."This is evidence that the story is complicated," said Tanmai Saxena, an M.D./Ph.D. student at the Keck School of Medicine at the University of Southern California. "The benefits of hormone therapy for relief of postmenopausal symptoms among women are clear, but the risks are more complicated than we had previously thought."

11 Aug 2010

Therapy News and Research

Venom-based nanoparticles improve gene therapy for fighting glioma

Einstein College receives grant to develop stem cell-based therapies

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

BMI indicates breast cancer risk in women using postmenopausal hormone therapy

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

TomTec releases new version of 2D Cardiac Performance Analysis package

Repros receives US patent for Androxal

Molecular imaging helps physicians determine patient suitability for ICD therapy

Cramer selects Neolane to support marketing communication programs for clients in healthcare practice

OptiNose's bi-directional nasal device delivering fluticasone effective in reducing nasal polyps in CRS patients

ITI signs NPWT contract with MAGNET

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Researchers to develop a prototype for laser based radiation therapy

Immunomedics receives additional patent for CD74 target

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Bluhm Cardiovascular Institute implants two Heartware ventricular assist devices

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Georgia Institute receives EUREKA grant to design brain tumor treatment

Study finds hormone replacement therapy increases breast cancer risk

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News